Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medivir Clears The Decks For Clinical Focus, Cuts All Preclinical Projects

Executive Summary

Medivir outlines plans to cut costs, reduce headcount and streamline priorities as the biotech focuses solely on four assets in clinical development.

You may also be interested in...



AbbVie Explores Uncharted Territory With DUB Inhibitor Neuroscience Deal

AbbVie has added Mission Therapeutics to its preclinical partnership roster with a neurology deal to develop DUB inhibitors in Alzheimer’s and Parkinson’s disease. 

Cancer-Focused Medivir Licenses AMR Centre Promising Superbug Assets

Medivir has licensed to the UK's AMR Centre exclusive worldwide rights to its superbug MBLI program in return for a share of eventual sales from generated therapies.

Medivir's Oncology Asset Purchase Seals TetraLogic's Death

Medivir, which recently reinvented itself as a solely oncology-based R&D company, is buying two programs for TetraLogic which will subsequently 'terminate all remaining employees'.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC124022

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel